Key result
Bosentan, but not BQ-123, significantly attenuated hypoxia-induced ANP release (P < 0.01), indicating it is partially modulated via interaction with endogenous endothelin.
Why the study?
Does endothelin mediate ischemia/hypoxia-induced atrial natriuretic peptide release in isolated rat hearts?
Population
Isolated rat hearts with non-distended atria perfused using a Langendorff apparatus
Comparison
Exogenous ET-1 (5 x 10 M) or ET receptor… vs Direct flow reduction or hypoxia without…
Design
Preclinical
Follow-up
30 minutes of ischemia/hypoxia followed by 30 minutes of…
Authors
Loading...
Hypothesis-generating for endothelin modulation of ANP in hypoxia; leaves open human translation and therapeutic relevance.
Does endothelin mediate ischemia/hypoxia-induced atrial natriuretic peptide release in isolated rat hearts?
p-value: p=<0.01
Endogenous endothelin partially modulates hypoxia-induced, but not ischemia-induced, ANP release in isolated rat hearts.
Zhang et al. (2004) studied Ischemia/hypoxia-induced ANP release. ET receptor antagonists (BQ-123 or Bosentan) or exogenous ET-1 vs. Control conditions (direct flow reduction or hypoxia without antagonists) was evaluated on ANP release (p=<0.01). Bosentan, but not BQ-123, significantly attenuated hypoxia-induced ANP release (P < 0.01), indicating it is partially modulated via interaction with endogenous endothelin.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: